Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

John Crabb, PhD

216.445.0425

John Crabb, PhD
Department: Ophthalmic Research
Location: Cleveland Clinic Main Campus
Mail Code i31
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.445.0425
WorkFax:216.445.3670
John Crabb, PhD
Department: Cellular and Molecular Medicine
Location: Cleveland Clinic Main Campus
Mail Code i31
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.445.0425
WorkFax:216.445.3670
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

John Crabb, PhD, joined Cleveland Clinic in 1998 as a full Staff member in the Department of Ophthalmic Research, Cole Eye Institute, with a secondary appointment in the Department of Cell Biology, Lerner Research Institute. He is a full Faculty member and Professor in the Department of Chemistry, Case Western Reserve University, and in the Departments of Ophthalmology and Molecular Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds adjunct professorships in the Department of Chemistry, Cleveland State University, and the School of Biomedical Sciences, Kent State University.   

A major focus of Dr. Crabb's research concerns age-related macular degeneration (AMD). Proteomic biomarker studies are directed toward developing a blood test for AMD to identify those at risk, before there is clinical evidence of the disease. Other proteomic studies in his laboratory focus on glaucoma biomarker discovery and the molecular details of the retinoid visual cycle. Information about the laboratory can be found online at www.lerner.ccf.erg/eye/crabb/.

Dr. Crabb received a Bachelor's Degree in biology and chemistry from Lewis & Clark College in Portland, Ore., and a doctorate in microbiology from the University of Kansas Medical Center, Kansas City, Kan. He pursued postdoctoral training in biological chemistry at the University of Michigan and in the biochemistry of vision at the University of Washington. Prior to joining the Cole Eye Institute, he was a Senior Scientist and Director of Protein Chemistry at the Adirondack Biomedical Research Institute in Lake Placid, N.Y. During the 14 years he was in upstate New York, Dr. Crabb maintained adjunct faculty appointments at the University of Vermont, Clarkson University and Albany Medical College. Prior to New York, he was an Assistant Professor and Director of the Protein Sequencing Facility in the Institute of Physiological Chemistry, Ruhr University, Bochum, Germany.

Dr. Crabb has served full 5-year terms on NSF and NIH grant review panels and is a member of the editorial boards of Experimental Eye Research and the Journal of Ocular Biology, Disease and Informatics. He has published more than 190 basic-science research articles and currently has research support from government, private and corporate sources.

Professional Highlights

  • Editorial Board, Experimental Eye Research, 1998-Present
  • Editorial Board, Journal of Ocular Biology, Diseases and Informatics, 2007 –  Present

Education & Fellowships

Doctorate - University of Kansas Medical Center
Microbiology
Kansas City, KS USA
1978
Undergraduate - Lewis & Clark College
Biology & Chemistry
Portland, OR USA
1971

Specialty Interests

age-related macular degeneration primary open angle glaucoma

Awards & Honors

  • Sandy and Tom Trudell Research Award, Foundation Fighting Blindness, 2003   
  • Steinbach Award, Ruth and Milton Steinbach, 2006 – 2009
  • Senior Investigator Award, Research to Prevent Blindness, 2007

Additional Training

  • Postdoctoral Scholar, Department of Biological Chemistry, University of Michigan, Ann Arbor, Mich., protein chemistry (mentor, M.J. Coon), 1978 – 1980
  • Senior Fellow, Department of Ophthalmology, University of Washington, Seattle, Wash., biochemistry of vision (mentor, J.C. Saari), 1980 – 1982

Innovations & Patents

  • U.S. Patent No. 7172874, Diagnostic Methods for Age Related Macular Degeneration, by Hollyfield JG, Salomon RG, Crabb JW, Gu X; granted February 6, 2007
  • Crabb JW, Salomon RG, Anand-Apte B, Ebrahem Q, Reganathan K (2006), Composition and Methods for Macular Degeneration. US Provisional Patent Application 60/832,898, filed 07/26/06
  • Kuttner-Kondo L, Hagstrom S, Crabb JW, Hollyfield JG, Medof ME (2007), Methods for Detecting Age Related Macular Degeneration in a Subject. US Provisional Patent Application, filed 03/02/07
  • Bhattacharya SK, Crabb JW (2006), Compositions and  Methods for Inhibiting Optic Nerve Damage. US Provisional Patent Application 60/773,359, filed 02/13/06; International Application PCT/US2007/003834, filed 2/12/07; International Publication Number WO 2007/095250, published 8/23/07

Memberships

  • American Society for Biochemistry and Molecular Biology
  • American Society for Mass Spectrometry
  • Association of Biomolecular Resource Facilities
  • Association for Research in Vision and Ophthalmology
  • The Protein Society

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/8/2014, Dr. Crabb has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English